News
Bio-tech firm develops 3D printed replacement cornea for human eyes
After successfully transplanting the first 3D-printed cornea in an animal, North Carolina company Precise Bio has recently announced the launch of a dedicated business for creating marketable, 3D-printed products for human eyes. Founded by scientists from the Wake Forest Institute of Regenerative Medicine, this company is developing bio-fabrication printers that can restore cells, tissues, and organs. Their proprietary technology, a 4D bio-printing platform, is said to resolve existing limitations presented by other bioprinters to enable more complex tissues to be engineered for transplants and treatments. By focusing on developing marketable products for the eye, the company aims to achieve rapid advancement in its field and move to overhaul the whole organ transplant system.
A cornea transplant with sutures still visible. | Credit: National Institutes for Health, National Eye Institute
When a cornea is damaged by disease or injury, a replacement is often needed to restore vision. Transplant surgery using donated corneas is an available solution, however, it relies on a deceased donor. While the waiting list in the United States is nearly non-existent, other countries require longer wait times, some over a year, before one is available. The Eye Bank Association of America estimates that around 10 million people suffer from corneal blindness that could potentially be restored via transplant surgery. An artificially manufactured cornea would overcome supply limitations while also contributing to the knowledge base to develop more complex organs such as hearts and livers.
The cornea is the transparent layer covering the front part of the eye that, along with the lens, accounts for about two-thirds of the eye’s optical power. It does not contain blood vessels, making it a prime candidate for bioprinting, the field of 3D printing involving biological materials. Bioprinters differ from traditional 3D printers in ways that might not be surprising given their name. Instead of heated filament applied in layers on a plate to build an object, layers of cells and biocompatible materials are printed to form tissue. Along with a lack of blood vessels, the layered structure of the cornea also makes it well suited for bioprinting.
Precise Bio refers to its printing technique used for the corneas and other biomaterials as “4D” over the usual “3D” label due to the curing stage for the printed cells. The fourth dimension referred to is time needed, 10-14 days specifically, for the bio-printed cells and fibers to connect themselves together for biological operation in a bioreactor that keeps them warm for the duration. Aryeh Batt, Precise Bio’s CEO, summarized this step in an interview with IEEE Spectrum: “Essentially, the biology does the work, but you have to put them in the correct environment to make it happen.”
Initial animal safety studies for the corneal transplant have already been completed, and now the company must clear some additional hurdles to begin human testing. One of the major proofs for Precise Bio will be the demonstration of normal behavior of the bio-printed products. For example, during production using the 3D/4D printer, the printed cells grow rapidly into the form needed in a way that does not occur in a normal eye. The company will have to demonstrate in clinical studies how this process is controlled and stopped before transplant.
The field of 3D bioprinting is a research area receiving a significant amount of attention due to its potential for developments in tissue engineering, drug delivery, and cancer studies. In fact, hundreds of scientific articles were published on the topic this year alone. As with most new technology, however, the challenge of moving a development out of the laboratory and into the consumer marketplace is significant, but Precise Bio hopes to meet it head on with its new dedicated business.
For more on bioprinting, watch the below Tedx Talk by Dr. Sam Wadsworth of Aspect biosystems Ltd.
Tesla stock (NASDAQ: TSLA) endured one of its sharpest single-day declines in years on July 23, tumbling approximately 14.5 percent and closing near $320 after opening the session around $374. The drop erased more than $140 billion in market value amid heavy trading volume and left the shares at multi-week lows.
The sell-off followed the company’s second-quarter 2026 results, released the previous evening. Tesla reported record revenue of $28.2 billion, up 26 percent year over year, driven by a Q2-record 480,126 vehicle deliveries. Energy storage deployments also rose strongly.
Tesla (TSLA) Q2 2026 earnings results: miss on EPS, beat on revenue
Yet profitability disappointed sharply. Operating income fell 57 percent to $398 million, compressing the operating margin to just 1.4 percent. Non-GAAP earnings per share came in at $0.33, well below the roughly $0.53 analysts had expected. Free cash flow turned negative by $1.1 billion as capital expenditures surged 142 percent to $5.8 billion, largely tied to accelerated spending on artificial intelligence, robotics, and autonomous systems.
The losses on capex were expected, as Tesla said it would be spending heavily in 2026.
Investors also reacted to lingering uncertainty surrounding key product timelines. During the Earnings Call, management reiterated ambitions for Robotaxi deployment and the Optimus humanoid robot, but offered limited new concrete milestones, renewing questions about execution pace that have long accompanied Tesla’s ambitious roadmap.
The magnitude of the decline places it among Tesla’s more severe one-day percentage losses since its 2010 initial public offering. Historically, the two largest single-day drops (split-adjusted) remain September 8, 2020, when shares fell 21.1 percent amid broader market volatility and valuation concerns, and January 13, 2012, with a 19.3 percent plunge during the company’s early growth struggles.
Other notable declines include an 18.6 percent drop on March 16, 2020, at the onset of pandemic-related market turmoil. Thursday’s move ranks roughly ninth on the all-time list but stands out as the steepest in more than a year.
Despite the short-term pain, Tesla’s long-term trajectory has repeatedly recovered from such volatility. The latest results underscore both the strength of its core automotive and energy businesses and the near-term costs of heavy investment in next-generation technologies.
Elon Musk clapped back at France’s decision to withhold the approval for Tesla’s Full Self-Driving (FSD) Supervised system, projecting a clear and blunt message to French Transport Minister Phillippe Tabarot, after he publicly rejected the technology in its current form.
Tabarot outlines several concerns with Tesla Full Self-Driving in a detailed video statement, where he said, “The safety trade-offs are not yet sufficient to authorize it as it currently stands,” he said. He emphasized that FSD is not a true self-driving system and that the driver remains fully responsible.
Key issues Tabarot also brought up included allowing speeding when surrounding traffic exceeds limits and what he believes are insufficient guarantees of driver attention during complex urban maneuvers such as lane changes, intersections, and roundabouts.
Delaying the approval of FSD in France will cost lives
— Elon Musk (@elonmusk) July 22, 2026
While acknowledging technological progress and France’s support for autonomous innovation, Tabarot stressed that deployment must prioritize road safety. He noted ongoing technical discussions with Tesla, the Netherlands, and other European partners, with further ecosystem meetings planned for the fall.
Musk’s rebuke highlights the human cost of regulatory caution. Tesla’s latest safety reports provide compelling data supporting accelerated adoption. In the most recent 12-month period, vehicles using FSD (Supervised) recorded one major collision per approximately 5.1 million miles driven, dramatically better than the U.S. national average of one crash per 698,000 miles.
Even Tesla vehicles driven manually with active safety features outperform the average by a wide margin. These figures come from billions of real-world miles of telemetry, showing FSD vehicles involved in far fewer incidents than both manual Teslas and the broader U.S. fleet.
Critics argue Tesla’s comparisons require careful scrutiny regarding reporting thresholds and fleet demographics, yet the data consistently positions FSD as a potential lifesaver. With road fatalities remaining a leading cause of death worldwide, Musk contends that proven safer technology should not face prolonged bureaucratic hurdles.
France’s measured approach reflects the broader European regulatory caution, which many, especially Musk, have been critical of in the past. However, as autonomous systems from Tesla and competitors like Waymo demonstrate superior safety in independent studies, pressure is mounting for harmonized approvals.
Musk’s warning carries the belief that every month of delay may equate to avoidable tragedies on European roads.
In a striking revelation that underscores the lucrative crossover between Big Tech and space exploration, Alphabet Inc., Google’s parent company, disclosed a massive $94.1 billion equity stake in SpaceX following the rocket company’s blockbuster initial public offering earlier this year.
The disclosure came in Alphabet’s quarterly filing, marking the first time the long-held private investment has been publicly valued at market prices. Google was an early backer, investing alongside Fidelity in 2015 with roughly $500-900 million at a time when SpaceX was valued around $12 billion.
That bet has delivered extraordinary returns, roughly a hundredfold, transforming a strategic play on satellite internet and launch capabilities into one of Alphabet’s largest assets.
Google, $GOOGL, has said they hold $94 billion in SpaceX, $SPCX, shares after IPO.
— unusual_whales (@unusual_whales) July 23, 2026
Of the total holding, approximately $80 billion remains subject to short-term post-IPO lockup restrictions, preventing near-term sales. An additional $14.1 billion faces longer-term restrictions, extending into the third quarter of 2027. This structure limits immediate liquidity but protects against market volatility as SpaceX transitions into public trading.
The SpaceX position contributed significantly to gains in Alphabet’s broader investment portfolio, which also includes a major stake in AI leader Anthropic. Combined, these holdings helped drive nearly $100 billion in investment gains during the second quarter, providing a substantial boost to net income amid ongoing AI spending pressures.
Analysts view the disclosure as validation of Alphabet’s venture strategy beyond its core search and cloud businesses. The investment aligns with deeper ties, including reported multi-billion-dollar deals for AI computing capacity on SpaceX infrastructure. As SpaceX advances Starship flights, Starlink expansion, and ambitious Mars goals under Elon Musk, Google’s stake positions it to benefit from the commercialization of space.
For Alphabet, the windfall highlights how patient, forward-looking bets in transformative sectors can yield outsized rewards. While lockups temper short-term impact, the holding cements SpaceX as a cornerstone of Alphabet’s diversified portfolio in an era where aerospace, AI, and connectivity increasingly intersect. Investors will watch closely as restrictions lift and SpaceX’s public performance unfolds.
Tesla stock tumbles after earnings, one of its sharpest single-day declines
Elon Musk is not happy about this Tesla Full Self-Driving approval delay
